Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Crome™ ICDs and CRT-Ds with BlueSync™ technology enable tablet-based programming and app-based remote monitoring, and provide proven exclusive shock reduction algorithms.
Download BrochureMeet Crome ICDs and CRT-Ds
With tablet-based programming and app-based remote monitoring, extended longevity, and 40 J on all shocks.
Mean longevity projections based on CareLink™ patient data.*
Option for 40 J energy delivery on all shocks, including the first.
MAXIMUM
DELIVERED
ENERGY<sup>†</sup>
40 J
MAXIMUM
STORED
ENERGY<sup>‡</sup>
47 J
Dual Chamber and CRT-D
CRT-D
BlueSync technology within Crome enables secure, wireless communication.
Tablet-based CareLink SmartSync™ device manager
Crome ICDs and CRT-Ds
MyCareLink Heart™ mobile app or MyCareLink Relay™ Home Communicator
CareLink network and the
Get Connected service
Manage alerts of clinically relevant events with additional CareAlert™ notifications.
Tachyarrhythmia Status:
Bradyarrhythmia Status:
Heart Failure Status:
Discover exclusive features and algorithms available in Crome ICDs and CRT-Ds.
Find additional feature information along with a variety of educational resources and tools.
Visit Medtronic AcademyThese values should not be interpreted as precise numbers. Individual patient results may vary based on their specific programming and experience.
Energy delivered at connector block into a 50 Ω ± 1% load.
Energy stored at charge end on capacitor.
A controlled, head-to-head study evaluating the comparative performance of device algorithms has not been done. AF detection accuracy rates determined from independent clinical trials are presented for reference.
Detection accuracy is compared using PPV, which is the percentage of all AT/AF episodes detected by the individual device detection algorithm that were adjudicated as true AT/AF.
Compared to matched control group.
Medtronic Compia MRI™ CRT-D, Amplia MRI™ CRT-D, and Claria MRI™ CRT-D Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236 EN.
Medtronic Crome™ HF Quad MRI SureScan™ Model DTPC2QQ device manual.
Medtronic Evera MRI™ XT DR SureScan™ and Evera MRI™ S DR SureScan™ Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236 EN.
Medtronic Crome™ DR MRI SureScan™ Model DDPC3D4 device manual.
Medtronic Visia AF™ VR Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236 EN.
Medtronic Crome™ VR ICD MRI SureScan™ Model DVPC3D4 device manual.
Sprenger M. Comparison of Manufacturer’s AT/AF Detection Accuracy across Clinical Studies. January 2015. Medtronic data on file.
Pürerfellner H, Gillis AM, Holbrook, Hettrick DA. Accuracy of atrial tachyarrhythmia detection in implantable devices with arrhythmia therapies. Pacing Clin Electrophysiol. July 2004;27(7):983-992.
Ziegler PD, et al. Accuracy of Atrial Fibrillation Detection in Implantable Pacemakers. Presented at HRS 2013 (PO02-08); Denver, CO.
Medtronic data on file. QADoc DSN026170, Version 2.0, “AT/AF Duration Performance Comparison.”
Kauffman ES, Israel CW, Nair GM, et al. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm. August 2012;9(8):1241-1246.
Nowak B, McMeekin J, Knops M, et al. Validation of dual-chamber pacemaker diagnostic data using dual-channel stored electrograms. Pacing Clin Electrophysiol. July 2005;28(7):620-629.
Crossley GH, Padeletti L, Zweibel S, Hudnall JH, Zhang Y, Boriani G. Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias. Pacing Clin Electrophysiol. July 2019;42(7):970-979.
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.